title: Synthesis, cytotoxicity testing, and structure-activity relationships of novel 6-chloro-7-(4-phenylimino-4H-3,1-benzoxazin-2-yl)-3-(substituted)-1,4,2-benzodithiazine 1,1-dioxides.
abstract: A new series of 16 6-chloro-1,1-dioxo-7-{4-[(4-R(1)-phenyl)imino]-4H-3,1-benzoxazin-2-yl}-3-(substituted amino)-1,4,2-benzodithiazines 7-22 was prepared in order to evaluate the cytotoxic activity against six human cancer cell lines. The structures of the new compounds were confirmed by IR, (1)H-, and (13)C-NMR, elemental analysis and in the cases of 11 and 31 by X-ray crystal structure analysis. This analysis showed that contrary to our earlier report the structures contain a benzoxazine ring instead of the proposed quinazolinone ring. The bioassay indicated that the benzodithiazine derivatives 7-22 possess cancer cell growth-inhibitory properties. Some compounds showed a high level of selectivity for certain cell lines. The most active compounds 11, 12, 16, 19, 21, and 22 exhibited potency higher or comparable to cisplatin. The compounds were particularly effective in LCLC-103H and MCF-7 cell lines with IC(50) values of 0.49-1.60 µM. Quantitative structure activity relationships (QSAR) revealed that a chloro substituent R(1) in the phenyl ring as well as the shape of the substituted amino group at R(2) (e.g., unsaturation is beneficial) are important for potency.
authors: Department of Chemical Technology of Drugs, Medical University of Gdańsk, Gdańsk, Poland.
authors: Elżbieta
authors: E
authors: Pomarnacka
authors: Anita
authors: A
authors: Kornicka
authors: Anna
authors: A
authors: Kuchnio
authors: Maike
authors: M
authors: Heinrichs
authors: Renate
authors: R
authors: Grünert
authors: Maria
authors: M
authors: Gdaniec
authors: Patrick J
authors: PJ
authors: Bednarski
references: Arch Pharm (Weinheim). 2008 Aug;341(8):485-90
references: 18618486
references: Bioorg Med Chem. 2007 Apr 1;15(7):2560-72
references: 17306551
references: Eur J Med Chem. 2003 Nov-Dec;38(11-12):991-9
references: 14642331
references: Farmaco. 2001 Aug;56(8):571-7
references: 11601642
references: Bioorg Med Chem. 2003 Apr 3;11(7):1259-67
references: 12628653
references: Bioorg Med Chem. 2009 Jun 1;17(11):3959-67
references: 19406645
references: Eur J Med Chem. 2006 May;41(5):633-9
references: 16488515
references: Pharmazie. 2001 Oct;56(10):763-9
references: 11683118
references: Farmaco. 2003 Jun;58(6):423-9
references: 12767381
references: J Med Chem. 2002 Jan 17;45(2):430-7
references: 11784147
references: Bioorg Med Chem. 2003 Aug 15;11(17):3673-81
references: 12901913
references: Anticancer Drugs. 2006 Jan;17(1):41-51
references: 16317289
references: Acta Pol Pharm. 1984;41(1):5-13
references: 6496140
references: J Med Chem. 2004 Jan 15;47(2):385-99
references: 14711310
references: Acta Pol Pharm. 1997 May-Jun;54(3):215-21
references: 9511447
references: Eur J Med Chem. 2007 Sep;42(9):1200-10
references: 17336427